ENG Genotype

If you have had unexplained nosebleeds since childhood, a close relative with the same pattern, or a lung or brain malformation found on a scan, this gene may hold the explanation. A fault in it is one of the two main causes of an inherited condition that quietly weakens blood vessels throughout your body.

Because the condition can hide silent malformations in your lungs and brain for years, knowing whether you carry the fault changes what you screen for and when. And because it runs in families, your result speaks for your parents, siblings, and children too.

What This Gene Does

ENG (the endoglin gene) carries the recipe for a protein called endoglin, which sits on the inner lining of your blood vessels. Its job is to help the cells that line vessels read a set of chemical growth signals (carried by proteins called BMP9 and BMP10) that tell vessels how to form and stay stable.

When one of your two copies of this gene is faulty, cells often make only about half the normal amount of endoglin. That shortfall, a situation scientists call haploinsufficiency, leaves vessels poorly stabilized and is the main mechanism, though some faults instead produce an altered protein that interferes with the working copy. Newborn and family studies confirmed that many affected carriers had reduced endoglin levels and no faulty protein reaching the cell surface, which fits the half-dose model.

The visible result is small clusters of dilated vessels near the skin and lining of the nose (telangiectases) and, more seriously, direct short-circuits between arteries and veins in internal organs (arteriovenous malformations, or AVMs).

Hereditary Hemorrhagic Telangiectasia Type 1

A pathogenic ENG variant is the cause of hereditary hemorrhagic telangiectasia type 1 (HHT1), first pinned to this gene in 1994. It is passed down in an autosomal dominant pattern, meaning a single faulty copy is enough to cause the condition, and each child of a carrier has a one in two chance of inheriting it.

The hallmark features are recurrent nosebleeds, telangiectases on the lips, tongue, fingers, and face, and AVMs in the lungs, brain, and liver. In HHT1 specifically, epistaxis and diagnosis both tend to arrive earlier in life than in the condition caused by the other main HHT gene.

Lung Malformations

The strongest and most actionable signal from an ENG result is a high rate of pulmonary AVMs, abnormal vessel connections in the lungs that let blood bypass the normal filtering the lungs provide. This matters because lung shunts can allow clots and bacteria to travel straight to the brain, raising the risk of stroke and brain abscess.

Across cohorts, lung AVMs are far more common in ENG-related disease than in the ACVRL1-related form. One recent series found them in 58.1% of ENG carriers versus 9.5% of ACVRL1 carriers, roughly six times as common. An Italian cohort reported 75% versus 44%, and a French-Italian network found symptomatic lung AVMs in 34.4% of HHT1 versus 5.2% of HHT2, about six times more often.

What this means for you: a confirmed ENG variant is a clear reason to get chest imaging to look for lung AVMs, even if you feel completely well, because these lesions are often silent and treatable when caught early.

Brain and Cerebral Malformations

ENG-related disease also carries a higher rate of brain and cerebral vascular malformations than the ACVRL1 form. In the Italian cohort, brain AVMs appeared in 20% of HHT1 carriers versus none of the HHT2 carriers, and cerebral abscesses were also more frequent in HHT1. Larger analyses confirm the same direction, with brain AVMs roughly five times more common in ENG carriers.

Pediatric studies show the same direction of effect, with ENG variants linked to lung AVMs, brain vascular malformations, and a combined pattern that carries both. A positive result is a reason to discuss brain MRI screening with an HHT specialist, since these lesions can be managed before they bleed.

How ENG Differs From the Other Main HHT Gene

HHT can also be caused by a variant in a related gene called ACVRL1, which produces HHT2. The two genes shape different patterns rather than one being uniformly worse. ENG carriers tend to be diagnosed younger and lean toward lung and brain malformations, while ACVRL1 carriers more often develop liver involvement, gastrointestinal bleeding, and anemia.

This is why an ENG result is not a simple good-or-bad verdict. It is a phenotype indicator: it points you toward the specific malformations to screen for, rather than telling you the disease will be more or less severe overall.

Why the Type of Fault Matters

The kind of variant can add information beyond the gene name. Faults that cut the protein short (truncating variants) made up 69.8% of ENG variants in one cohort, and truncating variants independently predicted anemia even when the gene label alone did not. So the exact change your report lists carries weight of its own.

It is equally important to know what the genotype cannot tell you. Two people with the identical ENG variant, even within the same family, can have very different degrees of disease. Part of the reason is that individual lesions can pick up a second, local genetic change in vessel cells over a lifetime, a layer that a germline result cannot capture.

A One-Time Result You Act On for Years

This is a fixed germline result. Your ENG genotype was set at conception and will read the same if you test again next year, so there is no trend to track and no reason to repeat the test itself unless a confirmatory method is needed to verify an uncertain call.

The value comes from what you do with it over time. If you carry a pathogenic variant, the tests worth repeating are the ones that track organ involvement and bleeding burden: a blood count and iron studies to catch anemia from chronic bleeding, and AVM imaging on a schedule your HHT specialist sets. Get a baseline of those companion tests now, then follow the surveillance interval your specialist recommends rather than waiting for symptoms.

When a Result Can Mislead

• Panel coverage: a negative result does not prove ENG is normal. Routine sequencing can miss large deletions, duplications, and rearrangements. Adding copy-number testing has uncovered ENG rearrangements in people whose standard sequencing was negative.
• Uncertain variants: an assay may report a change of unknown meaning (a variant of uncertain significance). This is not a diagnosis. It requires structural, family-segregation, or specialist review before it should influence any decision.
• Ancestry and prevalence: ENG and ACVRL1 dominance differs by population, so the meaning of a result depends partly on your background and cannot be inferred from prevalence patterns alone.
• Not a severity predictor: the genotype confirms inherited risk but does not forecast how mild or severe your disease will be, since expression varies widely between people and within families.

What to Do With an Unexpected Result

A positive result should trigger a concrete workup rather than watchful waiting. Involve a clinical genetics or HHT specialist, arrange chest imaging for lung AVMs and brain MRI for cerebral malformations, and offer cascade testing to biological relatives so carriers can start screening and noncarriers can stop unnecessary surveillance.

A negative result in someone with strong clinical features or family history is not the end of the road. Consider testing ACVRL1 and SMAD4, and broader panels that can catch HHT-like syndromes tied to genes such as RASA1, EPHB4, or GDF2. If your report lists a change of uncertain meaning, ask whether a confirmatory method by a different technique is warranted before it drives any decision.